Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Sweden
Finland
Denmark
Norway
Latest
Trending
Followed

Nightingale, Webcast, Half-year financial report 1 July–31 December 2025

By Inderes3/5/2026, 12:00 PM
Nightingale Health

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Teemu Suna
00:00 - 34:11

Good afternoon and welcome to the half-year results webcast of Nightingale Health. Today we have the following agenda. I will talk first about Nightingale Health in brief, summarizing the technology and our business. Then we go to the business targets of the current fiscal year. Then we will have a business update of the company. First half, and then we will proceed to the financial review. Finally, we will have a Q&A session. My name is Teemu Suna. I'm CEO and founder of Nightingale Health and also interim CFO. Let's start. So Nightingale Health, our mission is to build better healthcare for everyone. The company was founded in 2013 and is headquartered here in Helsinki. But we are a global company. We have laboratories in United States, United Kingdom, Japan, Singapore, and of course here. Here in Finland, we serve customers in B2B and B2C segments. And the focus is preventive healthcare and medical research. So, what is Nightingale Health all about? Our technology is building a global standard that will enable AI-powered preventive healthcare. The problem in healthcare at the moment is that there is no globally standardised clinical-grade way to measure health trajectories and intervention impact. So now, because we cannot measure health and health trajectories, the healthcare system is very reactive. So the healthcare system basically waits for people to get sick and then tries to do something about it. And the reason why it is like this is that we are missing a way to measure health and health trajectories. Nightingale's solution is that we take one blood sample, we run one test, and we get multi-disease risk detection and tracking. And this can be done at scale. For everyone, the technology has a world-leading track record. We have run more than 3 million samples. There are more than 900 peer-reviewed publications, and we have multi-market regulatory approvals to be able to serve the healthcare industry. And we are running labs around the world. And, about two years ago, we also started national implementation here in Finland. The opportunity with Nightingale is that Nightingale will become the globally standardized measurement layer that will power AI-native preventive healthcare applications. And now when AI is coming to all industries, it will also come to healthcare. But the challenge at the moment is that utilizing the current data in healthcare, in electronic health record systems, will not work because of the consistency and data quality. It's not there. And for AI to actually work, including its applications in healthcare, we need standardized data in the background. And this is what Nightingale can bring across the healthcare industry. So if we look at the solution in a bit more detail, as I said, we take one blood sample. It can be a venous sample or a fingerprick sample. We collect using our proprietary device. So the whole chain comes from Nightingale. So we have an end-to-end solution. Also, high quality of the results is ensured with the fingerprick samples. We run one test. The test itself is proprietary and only available from Nightingale Health, and then as a result, we detect the risk for heart attack, stroke, type two diabetes, chronic kidney disease, liver disease, and everything in one go. And then in addition, you get more than 40 clinical biomarkers. So Nightingale is not a traditional diagnostic company because traditional diagnostic companies and the kind of the whole diagnostic industry are basically focused on single biomarkers. And this is a very effective approach if you want to diagnose a disease. But prevention does not work like that because the idea of prevention is that you actually want to lower the risk of developing disease when people are still healthy. So, what we do is quantify the disease risk. And then with that information and data. We can build preventive healthcare applications. Why the time for preventive healthcare is now. The burden of chronic disease and cost pressure are accelerating all over the world. And these are the chronic diseases that are preventable. They represent something like 80% of healthcare costs. Because of this, healthcare is changing. Prevention is going mainstream. So there are more and more population-scale programs that try to bring preventive healthcare into reality. And then number three, all the AI applications, as I said, they need objective, standardized molecular data to guide prevention. If you only use different kinds of proxy signals, they work, but the quality of the analysis is not there. Repeatability is not there. Tracking is not there. There are a lot of challenges in healthcare, particularly when using AI for disease risk detection. We've been building the company for more than ten years already. Building this kind of a company. This is a long-term play. This is not something that happens overnight. I think it applies to all of the medical device industry. Particularly if you have a medical device that you want to roll out in population scale. So here you can see what Nightingale has been doing in market entry over the past ten years. So we started from Finland. So we established the laboratory in Finland in 2015. Then, the first step before establishing the laboratory is to conduct pilots without a local lab. Then once we get some comfort with the pilots, we build the local lab. Then we go and get the regulatory approvals. Then based on that, we can win local pilots. Then based on local pilots, we can win local reference deals. Then based on the reference deals, we can win high volume deals. And then based on the high volume deals, we can win broad market penetration. In Finland, we have almost completed the entire journey. We are in the high volume deals with our partner Terveystalo. More than 200,000 people have already been measured with Nightingale's technology. However, there is still one step to go, which is to adopt the technology in public healthcare and in all of the healthcare systems in a country. Now, what makes these market entries challenging is that you have to do the same thing in every country. So in Japan, we established a laboratory in 2019. We have made good progress, but it takes years. It's not something that happens very quickly. However, you can see that the pace is accelerating because the more we have been building different laboratories and market entries, the better we can package the market entry, the better we can make it work. We can make it work in the market. In Singapore, we are establishing the laboratory in 2024. And we are already quite advanced over there; the UK market entry is also set for 2024. Not as far as in Singapore and the US by 2025. So now, what we believe is that the market entries will significantly accelerate as we move forward. And we have several commercial discussions underway to expand the laboratories also beyond this list of countries. So my point is that the current lab rollout model is well standardized, and we are in a good position to continue expansion in these markets and enter new markets. But building all this has taken ten years. It's not easy. But on the other hand, it creates a very strong moat for Nightingale. Our business model is Nightingale Inside, meaning that we deliver our data to our customers and then they build the preventive health applications. This is to enable a very scalable model and allows us to run the technology across the world when we are not serving directly the end customer. The business model is simply price per sample. And here we have three different tiers. So basically, different customers have very different volumes. In Tier 1, we talk about longevity clinics. They typically have very low volumes. But then on the other hand, the unit price can be higher. And then when we go to Tier 3, we have national screening programmes, etc. where we have very big sample numbers. So the volume is high, but the unit price is low. And our pricing structure supports very, very well. All of the tiers. So that puts Nightingale as a growth company, I think, in a very strong position, because when we are offering our services, it has healthy gross margin. So when we build growth, the growth has very strong financial foundations. We have multiple active pilots and late-stage negotiations ongoing across the key segments. And this is basically enabled by multi-country lab availability. There is absolutely no way to do this business in a way that you try to make the deals and then you build the labs. It just doesn't work that way. You have to be in the country. You have to be present. There are some differences, for example, in Europe, within the European Union, of course, the samples can move between the countries. But if you look at the global picture, you have to bring the lab capacity and the lab capability locally available. The market we are looking at here, this is when I mentioned that these chronic diseases are 80% of healthcare costs. This is the largest healthcare market in the world. And when I say that, because healthcare is such a massive thing, in many governments, the healthcare budgets are 3 to 5 times larger than the military budgets. So this is a massive, massive, one of the biggest markets in the world. And then cardiometabolic burden, on which we are focused, that's the largest preventable burden. This is preventable global disease burden. The budgets are already there. Spending is already there. What is missing and what has been missing is how to make prevention measurable. So many times we hear people speaking that prevention is very problematic because if you, for example, have a lifestyle improvement program, even if you use some drugs, how do you quantify the effect of prevention? And I strongly believe that this is the single biggest reason why prevention has not broken through before. Because these kinds of technologies have not existed. But now with Nightingale, the key thing we can do is actually measure the impact of the actions that are being done in preventative healthcare. And then the opportunity here is that when we standardize the measurement layer that powers prevention across the whole industry. Why Nightingale, I mentioned we have been building the company for more than ten years. There's a lot of things we have achieved. Here is a list of selected benefits to work with Nightingale. We are heavily validated. More than 900 publications. This number, to our knowledge. It's next to none. We are global. We can actually serve our customers across the world. This is very scalable. This is built for population scale because our price point is very, very competitive against, for example, clinical chemistry. In many applications, especially when you go to prevention, we also win with a price point. We are a very efficient company. When we do a peer comparison, and by that I mean an international peer comparison, not a local or a Finnish comparison, running this kind of a global operation is financially very efficient. How we run it, we are independent. This is also something that maybe people don't think about often. There are not many status quo-independent global assets in blood testing, because much of the diagnostic industry is already tied to the existing system. Many of the players are actually connected already to the existing system. And then there are potentially some conflicts of interest. This is proprietary, only available from Nightingale, from the biotechnology to the applications. It's proprietary. We are publicly listed. We have transparent operations, professional governance. We have a massive database, the world's largest metabolomics database. Regulatory approvals. We are the first team that actually brought omics technology into healthcare. And then we are already in nationwide use. So I would say there is a lot to like. All right then let's move to the business targets for the current financial year. Our single target is to increase revenue by at least 50% compared to the previous financial year. We are on track with this. This is our current fiscal year. The revenue accumulation is very heavily weighted on the second half. So, we are reiterating this target. In the longer term, no changes here. But what we are building, we are building a global company; we very strongly believe that there is a huge market for prevention. It has to be done. Governments have to initiate preventative healthcare programs. And in that context, these goals are feasible. Then we go to the business update, and I will give a brief update of all of the geographical areas that we are working at the moment. It's been the past half-year. It has been the core focus to ramp up the commercial activities everywhere. And I think what we have managed to do, and what the team has managed to do across the world, is that we have heavily increased the sales activities, and how we build up the revenue is, of course, by selling more. And why have we only now started in the first half of this fiscal year? Building up the readiness to really ramp up the commercial operation. It takes a long time, but I think now we are in that position. And what I will share with you today is that there are many indications that sales activities are now increasing, in addition to an expanding pipeline. We have done new significant agreements and we have multiple pilot projects launched. Important thing to remember is that the sales cycles remain long. But then, on the other hand, what we now see in the sales and the customer feedback. I think the long-term growth prospect is very solid. So in Finland, we have a lot of sales activities ongoing across public sector stakeholders to evaluate how this technology could be adopted across the public sector. We are also doing commercial investigations to offer our remote blood testing to healthcare in Finland. Then, what we managed to achieve, we have a new strategic agreement with Terveystalo. What this changes is that, earlier we were working only in occupational healthcare with Terveystalo. Now we are moving to all of the Terveystalo customer segments, and the volumes we are running with Terveystalo are internationally very significant. Two pilots with public sector. We have two pilots in the public sector. These are very important to demonstrate how the technology also works in the public sector. And the problems in healthcare are largely the same. But when you move across different systems, then the implementation is also pretty different. Therefore, we need to start with piloting also in the public sector. In United Kingdom. We started last summer to strengthen the UK sales team on the ground, and I think this is now very important to appreciate that this only started last summer. In the first half, we achieved a significant increase in sales activities. We had a lot of engagements with public and private healthcare providers and pharma. First pilot projects are launched and several negotiations are ongoing to initiate new pilots. Then the rest of Europe that we manage commercially as a separate business. We also started last summer. And again, it's important to appreciate that the readiness to scale this out commercially has not been strong enough, because it doesn't help to approach customers if the product isn't ready. But now, based on the feedback, I think the product is there, and we have worked very hard to open discussions in more than ten countries. And now based on the feedback, we are continuing to expand the sales activities and the resourcing in sales. So several pilots already ongoing, and this is a very good achievement because the sales cycles are very long. In a relatively short time, we have managed to initiate multiple new pilots, and then some of the projects are moving to production stage negotiations. So, given the inherent long timelines of this business, I was talking earlier about building the company with a ten-year vision, now putting that vision in relation to what we've been building. I think the progress is very strong. In Singapore, we continued investments to expand the commercial team to accelerate sales. A very significant update that we did. So because we've been working in Singapore already for a while. And as I mentioned, having the right product-market fit is essential. So based on the feedback that we got from the market, we actually made a significant report update. So we updated our product. And now we have offered the new report and presented it to tens of customers. And now the reception is very, very strong. And when I compared the difference in the conversations with the customers, I think the tone is fundamentally different. So, based on this, I think there is a strong long-term growth potential in Singapore based on the market dynamics. It's a very significant health screening market and the customer feedback. So now in Singapore, first clinics are already ordering services under the updated report. The sample volumes are initially modest, but this is very typical for new markets. So it goes in stages. What we try to do in the ongoing half, we are increasing the number of clinics ordering the test and, with this, improving market penetration in Japan; we also made a lot of efforts to strengthen the sales team, which we succeeded to do, and based on this, we have new sales activities ongoing. We also have a similar feedback process that we did in Singapore. We have got good feedback from the customers. We will implement some updates to the business model as well as to the clinical report. And then these changes will be gradually implemented during the current fiscal year. So, during the ongoing fiscal half, we expect to see the results in the next fiscal year. We also initiated expansion of presence in medical research in Japan. Japan is a very special market. So otherwise, we manage medical research centralized globally from Finland. But Japan is a rather special market. And that's why we have now ramped up also local capabilities to promote the medical research in Japan. So recurring business in Japan is continuing. And the sample volumes from key customers are continuing. We have negotiations to close more key accounts in the market. So, due to the improved sales activities, I think we now also have good prospects to close more accounts. And then we have already signed new deals with medical research customers so that I think it's an early validation for the decision to have independent medical research sales capability in the Japanese market in the United States. We announced after the first half that we received the CLEP Permit in New York. This is a big milestone because this is something you, of course, need to clear before entering the US healthcare market and running the samples locally. And this is the difference to our previous position. Of course, we could offer our services internationally, but now having the local capability on the ground makes a huge difference. There are some steps still required under the CLEP permit that we need to do, but I think the biggest unknown for us has now been completed, and with many sales activities planned for the current year's second half, some deals are already in negotiation based on the concept of running samples in the New York lab. Then in the medical research market. With the team, we made a big effort, aiming to increase the sales activity. So ramping up the monthly prospects. And we managed to increase the number by tens of percent, which is a very strong result. There is strong interest towards Multiomics offering, which is a new offering. And we are continuing the investments into sales resources and activities. In the current year half, we won a significant project in Italy; we won a significant Multi-omics deal in Denmark. And then of course, several smaller projects ongoing. But the key message is that the prospect pipeline is growing. And that we are expecting to also bring a strong yield in winning cases. Then we move to the Financial Review. Couple of points regarding the numbers. The revenue increased by 4% compared to last year in the first half. We are still, as I said earlier, we have strong sales pipeline to support reaching the target of 50% revenue growth. And this is supported by the Aalborg project, because it always takes time before the revenues from that project are recognized. So that's why the current fiscal year is heavily weighted towards the second half. But the order book is strong, and that's why we are maintaining the target for the entire fiscal year that we gave earlier. But the order book is strong, and that's why we are maintaining the target for the whole fiscal year that we gave earlier. Then, a couple of points regarding the first half financials. I reiterate what we have said earlier, that the revenue growth target can be achieved without much pressure to increase the cash burn. So now the investments that we have done in the labs and the production capabilities, they can take more load. We have capacity to run samples. And because we have the capacity, the pressure to increase the cash burn is low. Even though the revenue can increase significantly. The net cash change was impacted by 2 million by the renewal of our lease agreement in the headquarter. All right. So that was it. And we have the last segment with Q&A. And I'd like to ask our chief operating officer to join me on stage. And I think there are some questions we can work through now.

Unknown 1
34:12 - 34:45

Yes. Good afternoon. Good afternoon. Our live audience, small live audience. And good afternoon, our audience also online. So let's kick off this Q&A session. I will be hosting it. So we will start with some questions that have come through online. And then we'll also have the opportunity for our audience to ask questions. So Teemu, it seems like a lot has been going on during the H1 period. So could you tell me, did the outcomes align with what you were expecting?

Teemu Suna
34:45 - 35:42

Yeah. So of course, every time you hope that you can show more in the numbers that we report. However, putting this in the scale of building the company for ten years, I'm more looking at the size of the pipeline and the amount of sales activities. So the actual things that we are doing all the time and with the long sales cycle, that is the indication that gives the best understanding where the company is going. And when I look at that, I'm actually very pleased. We made a huge change compared to a year ago. So in that sense, I think we are in a good position. And now this work we are doing, I'm confident that it will turn into results that then we can report also with these numbers.

Unknown 1
35:42 - 36:00

Great. Let's talk about the deals that you announced last year. So the big Aalborg University deal worth 2.5 million. What is the current status of that project and how much revenue was recognized during this first half of the fiscal year?

Teemu Suna
36:00 - 37:05

Yeah. So, the revenue from this project, which is very typical for research projects and also similar in healthcare, involves somewhat different dynamics in research. It usually takes a long time to get the samples to our laboratory and then running the samples and returning the results. So because of these reasons, this revenue is now projected for the ongoing half-year. So in the first half, no revenue was recognized from the project in healthcare; as I mentioned, the dynamics are a bit different there. It's more about starting to pilot, increasing gradually the numbers. So the low volume has different dynamics. But that's something that's part of this business. And I think it's rather natural. Also, when looking at the underlying reasons why it takes time to move the samples, and so on. So the slowness has a kind of a different dynamics.

Unknown 1
37:06 - 37:28

So because of these reasons, this revenue is now projected for the second half of the ongoing year. . So we can expect some revenue, probably this ongoing period. So, I would like to ask something about the US market. And you mentioned about the laboratory permit in the state of New York. So can you summarize what it really means and what can be expected in the short and long term for Nightingale Health?

Teemu Suna
37:28 - 38:57

Yes. So what the permit means is that you need to have the permit to offer your services to healthcare in the United States. Now the permit has different steps. So the first step was to get the laboratory approved, which was the biggest unknown for us, because it's always heavily connected to the local rules and regulations. Now when we have the first step done, then the following steps are more connected to looking at the performance of the individual biomarkers in our platform. This is something we have done across the world. So now we have much better confidence because blood is blood everywhere. So then demonstrating the performance, we are not expecting any differences with this. Of course, we need to go through the process carefully. But I think now we are more confident with that, and then what it means short term. We are now starting to negotiate agreements with our customers. And then in the longer term, I think that's the core of scaling up the business in the United States.

Unknown 1
38:57 - 39:07

So the rollout has a kind of a different dynamic. So also questions about our US partners. So can you elaborate a bit more? What's the status? Status with Boston Heart, for example.

Teemu Suna
39:07 - 39:46

So we have some partners where the deals were based on the concept that they would send the samples to our international labs, which technically works. But of course, the scaling up the business model has some limitations now because we got the permit. We are moving all of the partnerships to be run under the New York laboratory, but it still takes a bit of time to proceed with the approvals. Updates will follow once we move the approvals to the next stage.

Unknown 1
39:47 - 40:02

But of course, scaling up the business model has some limitations now that we have the permit. So let's go from the US to Singapore. You talked about Singapore already a bit, but can you provide us an overview about the collaboration with InnoQuest Diagnostics, and is there any notable outcomes so far?

Teemu Suna
40:02 - 41:09

In Singapore, the partnership with InnoQuest Diagnostics has enabled us to provide the technology very broadly in the market. A very important part of this is that Inno Quest has the logistics chains to all of the clinics, which is, of course, building, even though Singapore is a small geographical area. But building that kind of a system takes time. And then we managed to provide the product to many customers. We collected feedback. We needed to do some changes with the product. Now we have taken the new product to these same customers. And now I think the important point is to compare the feedback before and after. And I think now the product market fit is very encouraging, and we are also already in production. The new report is in production, and we are now working very closely with many customers to increase adoption.

Unknown 1
41:10 - 41:25

That's great. Then back to Finland. So Terveystalo has been a Nightingale's customer for a long time already. But now you're expanding even the partnership. What can we expect out of this extended partnership?

Teemu Suna
41:25 - 42:13

Yeah. Well, I think it's a very positive thing that Terveystalo is so convinced of our technology that they want to expand it to all of their processes. What happens next? In healthcare, all the sample volumes and scaling up the business is always about getting the technology as part of the existing healthcare workflows. So now we work together with Terveystalo to evaluate other workflows than the occupational health workflow and then increase the adoption through that. So at the moment we are discussing with them about the new workflows, where to utilize Nightingale's technology.

Unknown 1
42:14 - 42:34

Okay, let's then address, as you mentioned during your presentation, the further potential in Finland on the public side. So, regarding South Savo and North Karelia wellbeing services counties' collaborations, the market is eager to hear how these pilots are going forward and when decisions are being made about the future?

Teemu Suna
42:35 - 43:32

So, in the public sector, it's the same question. What are the workflows where you bring the technology and how you integrate that with the existing operations? In North Karelia, we are going to the occupational healthcare for the unemployed, where they have a very strong case with Terveystalo. So we can offer the same services as part of that workflow. So kind of defining what we've been doing, we've been defining the different workflows, how they will adapt the technology. I think we are pretty advanced with both of the well-being counties and there. You can expect some news in the coming months, how the rollout will proceed. And they, of course, will create a very important reference in the public sector.

Unknown 1
43:33 - 43:43

You are working actively in several markets. So are you planning to expand to any additional markets in addition to those you mentioned?

Teemu Suna
43:44 - 45:03

It's a very good question because now, regarding the markets and the laboratories, it's important to remember that this is largely laboratory-driven. So now these different laboratories I mentioned are five. They have been the laboratories that we have invested upfront. Because you just have to go there to be able to do any deal making. Now we have a lot of conversations in other markets as well, but there is much closer connection also to dealmaking. So it's very likely that when we expand to new markets, there is also significant customer agreement already in place. So it's closer to the commercial operation, and this may describe a lot about the maturity of the company. So now we start to be more and more in a position that we can negotiate the deal and bring the lab at the same time, because the customer can validate it, they can run it in the beginning, they can run the service with one of our international locations. And it's like a more natural expansion than with these new locations.

Unknown 1
45:04 - 45:18

So now we then work together with Terveystalo to evaluate the different other workflows than the occupational health workflow and then increase the adoption through that. Okay, as you mentioned during your presentation, there's still something to gain in Finland on the public side. Let's then wrap up. Revenue has increased slightly for this first half, but the fiscal year target is still some way off. So how confident are you in reaching the target?

Teemu Suna
45:18 - 46:09

So we have the order book to make the numbers. I think it's as convincing as it can be. Of course, there is the question about execution and there are risks around the execution. However, we have also a lot of insights with these customers, with Aalborg, with some other projects as well. So because of that, we are reiterating the goal to increase the revenue by 50%. I think the situation is actually pretty good because you have the orders. I think that's, of course, I understand the market is looking at the numbers we report. But the real question to me. Do you have the orders? And we have the orders.

Unknown 1
46:11 - 46:22

Great. So, final question from me. Before we go to our live audience, what can we expect from the second half of this fiscal year?

Teemu Suna
46:22 - 47:28

Yeah. So, heavy focus on increasing the sales activities. To get sales, you have to sell. And now I think the product and the maturity of the company. Now we are there. So that's why a lot of effort is being used to increase the commercial activities. And it's not only about just hiring more salespeople. This kind of business doesn't work that way. It's more about being smart with the activities, being more targeted, being able to better discuss with the customers and sell the value. Offer the value. It's more about that. So all the focus is around that. And then all of the development, our data teams, and our software development – everyone is supporting these pilots and new projects to bring the value to the customers they are looking to get.

Unknown 1
47:29 - 47:37

Thank you Teemu. This was the final question. And then we move to our live audience. Any questions here? Yes, please.

Unknown 2
47:38 - 47:58

So, the deal is that it's not a Multiomics deal. Mr. Starting from the second half outlook, it was already discussed, but just wanted to check if you think the Aalborg contract will be delivered in full during the second half of the fiscal year. Michael. And then our pipeline is strong also outside of the deal. Danske Bank markets. A couple of questions. Starting from the second half outlook, it was already discussed, but just wanted to check if you think the Aalborg contract will be delivered in full during the second half of the fiscal year.

Teemu Suna
47:59 - 48:34

That is currently the expectation, and we are having active dialogue with the customer. But it's also not like a one and zero situation. Our pipeline is strong also outside of the deal. So we are looking at the big picture and then putting the pipeline together. We have good confidence that we will reach the target.

Unknown 2
48:36 - 48:52

Thanks. And then there were a couple of new deals you announced today. Starting from the Italian contract. What will be the timing of delivery on this one? And can you comment on the gross margin? Is it similar to the contract or better?

Teemu Suna
48:52 - 50:01

So, the deal with, it's a deal that is not a Multiomics deal. So a customer has ordered our NMR platform. At the moment, the orders with the NMR platform have a stronger gross margin than the Multiomics deals. There are many reasons for this. One reason is that in the Multiomics space, we also want to aim to win the market and aim to be very, very competitive with the pricing because it is an increasing marketplace. And the competition is strong at the moment. And then for the revenues, usually also the deals that we do with the NMR platform often allow us to predict a bit better when the revenues will be recognized.

Unknown 2
50:03 - 50:07

Okay, so would it be already in the second half of the year? Think about this Italian contract.

Teemu Suna
50:08 - 50:14

The Italian contract. It's ongoing, but I cannot comment on the details more.

Unknown 2
50:15 - 50:26

We need to have the process together with Terveystalo to integrate with clinical workflows. And then the other contract was with Terveystalo extension. Are you expecting more revenues from Terveystalo on the back of this extension?

Teemu Suna
50:26 - 51:39

Yes. But the question is that now, making this kind of a deal doesn't automatically mean that the revenues will start growing. We need to have the process together with Terveystalo to establish clinical workflows. They will adopt the technology. And that's, if you think about it from a very practical point of view, that as a healthcare provider, you have ongoing operations, if you make changes, the timing of those changes. Training of people using the technology. Maybe also educating the customers. So there are several steps to consider. And that's why making a deal doesn't immediately mean that there is revenue. But I think what making the deal means is that we are in a very good position to do the expansion, because without the deal there is no conversation about the expansion. So that's why we are very pleased about the deal. And it shows the trust from Terveystalo towards our technology.

Unknown 2
51:40 - 51:49

And then wanted to check, you may have said this, have you booked revenues from this wellbeing service county deal in Finland already?

Teemu Suna
51:49 - 52:14

Yeah. So the wellbeing services county deals, they are pilots. So we are not expecting to book revenues from them. And the scope of the pilots is like a rather limited, and the intention is to demonstrate how the technology integrates into the public healthcare domain as well.

Unknown 2
52:15 - 52:35

Okay. Then moving on to CapEx, how should we think about CapEx outlook for fiscal 26? Is it going to be on a similar level? And then last year, I think you mentioned that you have plans to open new labs. When will those happen?

Teemu Suna
52:37 - 53:27

I think we can expect a similar level for CapEx. However, of course, if there is a laboratory expansion in a new country, then there will be CapEx involved, but it's a very different situation. As I mentioned then, it's usually a business deal aligned with the potential CapEx. So I would not see additional CapEx as a concern, provided there is a business deal that also takes the revenue up at the same time. And as I mentioned earlier, Nightingale can build healthy growth because the gross margin structure, particularly with the NMR technology, is actually very good.

Unknown 2
53:28 - 53:35

Okay. So if you were to open new labs, you would have customers with revenue commitments.

Teemu Suna
53:35 - 53:53

Some form of a deal. The deals will be very, very different. But that's the idea that it's not setting up a laboratory before having the customer deal. So these are now going more hand in hand because we have already built the reference laboratories across the world.

Unknown 2
53:54 - 54:10

Okay. And then, final question. You talked about focus on sales activities. Just curious, how is the funnel looking, and are you expecting to close material deals during the second half of the year in order to grow also next year?

Teemu Suna
54:10 - 54:58

Yeah. If I look at the pipeline, definitely. We are expecting to close a material deal. Within this half, of course, the sales cycles are very long and it's difficult to predict still at this stage of the development. However, if I compare the pipeline size and quality, what it is today and what it was in August, it's fundamentally different, which justifies the expectation that we will close a material deal before the end of the fiscal year. And that's, of course, the target to then build up the Revenue growth also in the next fiscal year.

Unknown 2
54:58 - 55:12

Yeah. And maybe a follow on question, when you look at the quality of the pipeline, are we talking about mostly research opportunities or do you also have medical deals in the pipeline?

Teemu Suna
55:12 - 55:57

Both. I would say that earlier, the pipeline was very heavily weighted toward research business. And still, the research business is the part of the business that has a substantial role in the revenue growth. However, what we have managed to do over the past six months in the healthcare pipeline has also changed that quite substantially. So now when I look at the two pipelines, there is an equal opportunity from both sides to bring a substantial deal before the end of the fiscal year.

Unknown 2
55:57 - 55:58

Okay. As I mentioned then, it's usually a business deal aligned with the potential CapEx.

Teemu Suna
55:59 - 55:59

If I look at the pipeline, definitely.

Unknown 1
56:00 - 56:10

Thank you. So it has become the time to end this Q&A session. Do you have any final words that you would like to give at this point?

Teemu Suna
56:10 - 58:32

So I think we are transforming this kind of a company from a very strong technology focus, having built it for several years, bringing products to the market, finding product-market fit, and then finally moving to becoming a sales organization. It's not a very easy journey. But now when I look at the results, especially through the pipeline and sales, I think we are making strong progress in six months. I think this transformation has taken very big steps, and I'm expecting that over the current half-year, we can make similar progress. So I'm very excited. I'm also very excited when I look at the market, as there is more and more interest in prevention. There is more and more interest in blood testing. There is more and more thinking around risk detection rather than individual biomarkers. So, thinking beyond the biomarkers that we've been talking about for years already. And then the AI is a huge trend that I believe is very beneficial for us, because if you want to build a good preventive healthcare system powered by AI, what is your data to connect to the risk? If you use only variable data, well, you are looking at the proxy signals mostly. If you use some digital data from the internet. Again, it's a proxy signal. If you really want to understand the risk, which is the core of prevention, you need the molecules. It's molecular. It's an issue of molecular medicine which the algorithms will not solve. So you need the data. And we are one of the most advanced companies in the world to bring the data. So I think that's one of the megatrends that I believe can be very positive and beneficial for Nightingale. So very excited. And we will keep working very hard.

Unknown 1
58:32 - 58:38

Exactly. So it has become the time to end this Q&A session. We will end the session here now. And thank you for following.

Teemu Suna
58:40 - 58:49

Yes. So that's it. We will return in six months. And, thank you for listening and have a good day.

Continue to the webcast
Pierce Group, Audiocast, Q3'26
Language: English11/13/2026, 8:00 AM
Göran Dahlin Good morning, everyone, and welcome to Pierce Group's presentation of our Q3 2026 interim results. Next slide, please. I am Göran Dahlin, CEO of Pierce Group, and I am with Fredrik Kjellg…
Surgical Science Sweden, Audiocast, Q3'26
Language: English11/12/2026, 10:00 AM
Tom Englund Hi everyone, and welcome to this earnings call for Surgical Science for the third quarter of 2026. My name is Tom Englund. I am the CEO. And with me today is our CFO, Anna Ahlberg. I wil…
ExpreS2ion Biotech – Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 9:00 AM
ExpreS2ion is expected to release its Q3 2026 interim report on 12 November 2026. Later the same day at 10.00, ExpreS2ion’s CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.
Meko Services AB, Q3'26
Language: English11/12/2026, 8:00 AM
Pat Thank you. Good morning, and welcome to MEKO's presentation of the third quarter of 2026. I am here with our CFO, Christy Johansson, and I will begin with an overview of the quarter and some of th…
WeSports Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Unknown 1 It. Ted Sporre Welcome to our Q3 release presentation. As you know, we have already shared preliminary figures for sales and EBITDA for this quarter, but today we complete the picture. We wi…
Nordrest Holding, Audiocast, Q3'26
Language: Swedish11/12/2026, 8:00 AM
Thomas Dahlstedt Hej och välkomna! Vi ska idag presentera Nordrests senaste kvartal och tillika resultatet för perioden. Jag som pratar nu heter Thomas Dahlstedt och är grundare och tillika VD för bol…
Karnov Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Pontus Bodelsson Welcome, everyone, to Karnov Group's earnings conference, where we will present the outcome of the third quarter of 2026. Please go to slide two. I am Pontus Bodelsson, President and…
Fasadgruppen Group, Audiocast, Q3'26
Language: English11/12/2026, 7:15 AM
Magnus Blomberg Perfect. Good morning and welcome to the Fasadgruppen presentation of our results for the third quarter 2026. My name is Magnus Blomberg. You have met me before. I am the CFO of Fasadg…
Munters AB, CMD
Language: English11/11/2026, 1:00 PM
Lena Dauvergne Good. Good afternoon everyone, and a warm welcome to Stockholm, to ESSEX and to Montage Capital Markets Day 2026. Montage Capital Markets Day 2026. It is really good to see so many of y…
Cinclus Pharma, Audiocast, Q3'26
Language: English11/11/2026, 1:00 PM
Christer Ahlberg Thank you. Hello and welcome to the Cinclus Pharma third quarter 2026 earnings call. I am Christer Ahlberg, CEO of Cinclus Pharma, and with me today is our CFO, Magnus Christensen. We…
Proact IT, CMD
Language: English11/11/2026, 12:30 PM
Unknown 1 The world of data is constantly changing. Breaches are rising, and attacks are getting more advanced. Regulation drives the need for data sovereignty. Data has to be available. Critical busi…
Ferronordic AB, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Henrik Good morning, everyone, and welcome to our presentation of the third quarter of 2026. During the quarter, we saw higher earnings, and growing aftermarket revenue was up 15% to 1.2 billion Swedi…
BICO, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Anders Fogelberg Good morning, everyone, and welcome to BICO's earnings call for the third quarter of 2026. I am Anders Fogelberg, President and CEO of BICO. And joining me today is our Group CFO, Ewa…
Catena Media, Audiocast, Q3'26
Language: English11/10/2026, 5:00 PM
Manuel Stan Good afternoon. Good evening, everyone. Welcome to the Catena Media Q3 Interim Report. I am Manuel Stan and today I'm joined by our Chief Financial Officer, Michael Gerrow. Today we will b…
Ellos Group, Q3'26
Language: English11/10/2026, 8:00 AM
Hans Ohlsson Live. Good morning, everyone, and welcome to the second presentation for Ellos Group as a listed company. We have 45 minutes today for the presentation. And there is a hard stop. After th…
Scandic Hotels Group, Audiocast, Q3'26
Language: English11/10/2026, 8:00 AM
Jens Mathisen Thank you so much, and good morning, everyone, and thank you for joining us for the Q3 presentation. I am Jens Mathisen, CEO of Scandic. And joining me is our CFO, Pierre Carstensen. We…
Svevik Industri, Q3'26
Language: Swedish11/6/2026, 9:00 AM
Johan Hårdén Tack så mycket! Hello and welcome to this hearing regarding the Q3 2026 interim report. We have an agenda where we intend to introduce ourselves to all the new shareholders as well. Kort…
Attendo, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Martin Tivéus Good morning, everyone, and thank you for joining us. Today, we will present our results for the third quarter of 2026. I am pleased to announce that this is the strongest quarter for At…
Cavotec, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
David Pagels Good morning and welcome to Cavotec's Q3 2026 presentation. I am David Pagels, the CEO of Cavotec. And together with me today, I have our new CFO, Christoffer Robertsson. I would like to…
Fractal Gaming Group, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Jonas Good morning, everyone, and welcome to Fractal's Q3 2026 presentation. Today, we'll take you through our results, the progress that we've made, and our priorities ahead after a difficult first h…